Design for additive manufacturing: trends, opportunities, considerations, and constraints

© 2016 CIRP. The past few decades have seen substantial growth in Additive Manufacturing (AM) technologies. However, this growth has mainly been process-driven. The evolution of engineering design to take advantage of the possibilities afforded by AM and to manage the constraints associated with the technology has lagged behind. This paper presents the major opportunities, constraints, and economic considerations for Design for Additive Manufacturing. It explores issues related to design and redesign for direct and indirect AM production. It also highlights key industrial applications, outlines future challenges, and identifies promising directions for research and the exploitation of AM's full potential in industry

sj-docx-1-jet-10.1177_15266028231198033 – Supplemental material for Comparative Evaluation of Two Paclitaxel-Coated Stents in an Experimental Setting

Supplemental material, sj-docx-1-jet-10.1177_15266028231198033 for Comparative Evaluation of Two Paclitaxel-Coated Stents in an Experimental Setting by Alexandre Pouhin, Raphaël Coscas, Valentin Crespy, Olivia Poupardin, Jean-Paul Pais-De-Barros, Olivier Bouchot, Alain Bernard and Eric Steinmetz in Journal of Endovascular Therapy</p

Hemodynamic and respiratory parameters during ILP procedure.

<p>Hemodynamic and respiratory parameters during ILP procedure.</p

Dose-response curves after in vitro exposure for 30 min of CRC cells SW480, HT28, HCT116 and HCT8 with the lung effluent collected at the end of the ILP procedure.

<p>Cells were exposed to different dilutions (10%, 50% and 100%) of the lung effluent.</p

Chiang scores at the end of the ILP procedure and one month later.

<p>Chiang scores at the end of the ILP procedure and one month later.</p

Figure 1

<p>A- IC50 values after in vitro exposure for 30 min of CRC cells SW480, HT28, HCT116 and HCT8 with Oxaliplatin, 5 FU, Cisplatin, GEM, Irinotecan and Raltitrexed. B- Dose-response curves after in vitro exposure for 30 min of CRC cells SW480, HT28, HCT116 and HCT8 with Oxaliplatin, 5 FU, Cisplatin, GEM, Irinotecan and Raltitrexed. C- Dose-response curves after in vitro exposure for 30 min of CRC cells SW480, HT28, HCT116 and HCT8 with combination of GEM and Raltitrexed.</p

Figure 3

<p>A- Perfusion inflow in the isolated lung perfused with gelatin (580±178.88 ml/min), GEM 20 µg/ml (257.14±202.62 ml/min) and GEM 100 µg/ml (210+/−138.92 ml/min) during 30 min (p = 0.0055). B- Perfusion pressure in the isolated lung perfused with gelatin, GEM 20 µg/ml, and GEM 100 µg/ml during 30 min. C- Mean left pulmonary artery pressure before and after ILP with gelatin, GEM 20 µg/ml and GEM 100 µg/ml during 30 min (p = 0.7187).</p